{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T10:09:53Z","timestamp":1768471793883,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T00:00:00Z","timestamp":1662768000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.htct.2022.08.002","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T09:07:41Z","timestamp":1663664861000},"page":"266-274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil"],"prefix":"10.1016","volume":"45","author":[{"given":"Vania","family":"Hungria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2478-5354","authenticated-orcid":false,"given":"Ana Alfonso","family":"Pi\u00e9rola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8212-1620","authenticated-orcid":false,"given":"Jayr Schmidt","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8599-4731","authenticated-orcid":false,"given":"Edvan","family":"Crusoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto Jos\u00e9 Pessoa de Magalh\u00e3es","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0140-9548","authenticated-orcid":false,"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5236-7785","authenticated-orcid":false,"given":"Paula","family":"Rodr\u00edguez-Otero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.htct.2022.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.7150\/ijms.46811","article-title":"Efficacy and safety of CAR-T therapy for relapse or tefractory multiple myeloma: A systematic review and meta-analysis","volume":"18","author":"Yang","year":"2021","journal-title":"Int J Med Sci"},{"issue":"4","key":"10.1016\/j.htct.2022.08.002_bib0002","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.htct.2022.08.002_bib0003","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2019.09.621","article-title":"Treatment options for triple-class refractory multiple myeloma","volume":"20","author":"Mikhael","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.htct.2022.08.002_bib0004","unstructured":"CARVYKTI\u2122 (ciltacabtagene autoleucel) suspension for intravenous infusion. Highlights of prescribing information 2022."},{"issue":"3","key":"10.1016\/j.htct.2022.08.002_bib0005","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"Hayden","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.htct.2022.08.002_bib0006","series-title":"Anvisa Approves Advanced Therapy Product for Cancer Treatment","year":"2022"},{"key":"10.1016\/j.htct.2022.08.002_bib0007","series-title":"Anvisa Approves Advanced Cancer Therapy Product Registration","year":"2022"},{"key":"10.1016\/j.htct.2022.08.002_bib0008","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.3389\/fimmu.2018.01821","article-title":"Targeting B cell maturation antigen (BCMA) in multiple myeloma: Potential uses of BCMA-based immunotherapy","volume":"9","author":"Cho","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.htct.2022.08.002_bib0009","unstructured":"ABECMA (idecabtagene vicleucel), suspension for intravenous infusion. Highlights of prescribing information 2021."},{"issue":"8","key":"10.1016\/j.htct.2022.08.002_bib0010","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N Engl J Med"},{"issue":"15 Suppl","key":"10.1016\/j.htct.2022.08.002_bib0011","doi-asserted-by":"crossref","first-page":"8016","DOI":"10.1200\/JCO.2021.39.15_suppl.8016","article-title":"Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: updated KarMMa results","volume":"39","author":"Anderson","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10297","key":"10.1016\/j.htct.2022.08.002_bib0012","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.htct.2022.08.002_bib0013","article-title":"Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed\/refractory multiple myeloma: CARTITUDE-1 2-year follow-up","author":"Martin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Suppl 3","key":"10.1016\/j.htct.2022.08.002_bib0014","first-page":"29","article-title":"Educating multidisciplinary care teams, patients, and caregivers on CAR T-cell therapy","volume":"10","author":"Beaupierre","year":"2019","journal-title":"J Adv Pract Oncol"},{"issue":"2","key":"10.1016\/j.htct.2022.08.002_bib0015","first-page":"27","article-title":"Management across settings: an ambulatory and community perspective for patients undergoing CAR T-cell therapy in multiple care settings","volume":"23","author":"Beaupierre","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"Suppl 2","key":"10.1016\/j.htct.2022.08.002_bib0016","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/j.htct.2021.09.006","article-title":"Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. VI: Accreditation process","volume":"43","author":"De Santis","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"1","key":"10.1016\/j.htct.2022.08.002_bib0017","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","article-title":"A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial","volume":"34","author":"Facon","year":"2020","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.htct.2022.08.002_bib0018","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.htct.2022.08.002_bib0019","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood-2020-134322","article-title":"Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in elderly patients with relapsed and refractory multiple myeloma: KarMMa Subgroup Analysis","volume":"136","author":"Berdeja","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.htct.2022.08.002_bib0020","series-title":"Highlights of Prescribing Information","year":"2010"},{"issue":"1","key":"10.1016\/j.htct.2022.08.002_bib0021","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/s41598-021-04296-3","article-title":"The differential effects of tumor burdens on predicting the net benefits of ssCART-19 cell treatment on r\/r B-ALL patients","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"issue":"Suppl 1","key":"10.1016\/j.htct.2022.08.002_bib0022","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-134319","article-title":"Idecabtagene vicleucel (ide-cel, bb2121) in relapsed and refractory multiple myeloma: Analyses of high-risk subgroups in the KarMMa study","volume":"136","author":"Raje","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.htct.2022.08.002_bib0023","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.bbmt.2017.06.014","article-title":"Hematopoietic cell transplantation-specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation","volume":"23","author":"Berro","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.htct.2022.08.002_bib0024","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/bmt.2011.110","article-title":"The EBMT risk score","volume":"47","author":"Gratwohl","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"Suppl 1","key":"10.1016\/j.htct.2022.08.002_bib0025","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2020-134369","article-title":"Effects of prior alkylating therapies on preinfusion patient characteristics and starting material for CAR T cell product manufacturing in late-line multiple myeloma","volume":"136","author":"Rytlewski","year":"2020","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2022.08.002_bib0026","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1","key":"10.1016\/j.htct.2022.08.002_bib0027","first-page":"26","article-title":"Hospital pharmacist's roles and responsibilities with CAR-T medicines","volume":"44","author":"Moreno-Martinez","year":"2020","journal-title":"Farm Hosp"},{"issue":"Suppl 2","key":"10.1016\/j.htct.2022.08.002_bib0028","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/j.htct.2021.09.004","article-title":"Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. IV: CAR-T cell therapy for multiple myeloma patients","volume":"43","author":"Maiolino","year":"2021","journal-title":"Hematol Transfus Cell Ther"},{"issue":"4","key":"10.1016\/j.htct.2022.08.002_bib0029","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.htct.2022.08.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.100596","article-title":"CAR-T - and a side order of IgG, to go? - Immunoglobulin replacement in patients receiving CAR-T cell therapy","volume":"38","author":"Hill","year":"2019","journal-title":"Blood Rev"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922013049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2531137922013049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T13:36:11Z","timestamp":1762868171000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2531137922013049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["S2531137922013049"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2022.08.002","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy for multiple myeloma: a practical toolkit for treatment in Brazil","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2022.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}